152 related articles for article (PubMed ID: 19365855)
1. Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast.
Lenkinski RE; Wang X; Elian M; Goldberg SN
Magn Reson Med; 2009 Jun; 61(6):1286-92. PubMed ID: 19365855
[TBL] [Abstract][Full Text] [Related]
2. Application value of 3T ¹H-magnetic resonance spectroscopy in diagnosing breast tumors.
Vassiou K; Tsougos I; Kousi E; Vlychou M; Athanasiou E; Theodorou K; Arvanitis DL; Fezoulidis IV
Acta Radiol; 2013 May; 54(4):380-8. PubMed ID: 23436823
[TBL] [Abstract][Full Text] [Related]
3. Human breast lesions: characterization with proton MR spectroscopy.
Roebuck JR; Cecil KM; Schnall MD; Lenkinski RE
Radiology; 1998 Oct; 209(1):269-75. PubMed ID: 9769842
[TBL] [Abstract][Full Text] [Related]
4. Effect of contrast agent on the results of in vivo ¹H MRS of breast tumors - is it clinically significant?
Baltzer PA; Gussew A; Dietzel M; Rzanny R; Gajda M; Camara O; Reichenbach JR; Kaiser WA
NMR Biomed; 2012 Jan; 25(1):67-74. PubMed ID: 21557368
[TBL] [Abstract][Full Text] [Related]
5. Quantitative multivoxel proton chemical shift imaging of the breast.
Sijens PE; Dorrius MD; Kappert P; Baron P; Pijnappel RM; Oudkerk M
Magn Reson Imaging; 2010 Apr; 28(3):314-9. PubMed ID: 20071119
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance spectroscopy of the breast at 3T: pre- and post-contrast evaluation for breast lesion characterization.
Kousi E; Tsougos I; Vasiou K; Theodorou K; Poultsidi A; Fezoulidis I; Kappas C
ScientificWorldJournal; 2012; 2012():754380. PubMed ID: 22645448
[TBL] [Abstract][Full Text] [Related]
7. ¹H-magnetic resonance spectroscopy of the breast at 3.0-T: comparison of results obtained before and after administration of gadolinium-based contrast agent.
Kawai H; Naganawa S; Satake H; Ishigaki S; Sakurai Y; Mori M; Maruyama K
J Magn Reson Imaging; 2012 Mar; 35(3):717-22. PubMed ID: 22095613
[TBL] [Abstract][Full Text] [Related]
8. Study of single voxel 1H MR spectroscopy of bone tumors: differentiation of benign from malignant tumors.
Zhang J; Cheng K; Ding Y; Liang W; Ding Y; Vanel D; Cheng X
Eur J Radiol; 2013 Dec; 82(12):2124-8. PubMed ID: 22169357
[TBL] [Abstract][Full Text] [Related]
9. Effects of contrast material on the metabolite ratios in single-voxel MR Spectroscopy of intraaxial brain tumors.
Alkan A; Burulday V; Oztanir N; Dogan M; Erbay MF; Kocak A; Aralasmak A
Med Hypotheses; 2012 Aug; 79(2):129-31. PubMed ID: 22560442
[TBL] [Abstract][Full Text] [Related]
10. Comparative Investigation of Single Voxel Magnetic Resonance Spectroscopy and Dynamic Contrast Enhancement MR Imaging in Differentiation of Benign and Malignant Breast Lesions in a Sample of Iranian Women.
Faeghi F; Baniasadipour B; Jalalshokouhi J
Asian Pac J Cancer Prev; 2015; 16(18):8335-8. PubMed ID: 26745081
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 1H-magnetic resonance spectroscopy of breast cancer pre- and postgadolinium administration.
Joe BN; Chen VY; Salibi N; Fuangtharntip P; Hildebolt CF; Bae KT
Invest Radiol; 2005 Jul; 40(7):405-11. PubMed ID: 15973131
[TBL] [Abstract][Full Text] [Related]
12. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy.
Sardanelli F; Fausto A; Di Leo G; de Nijs R; Vorbuchner M; Podo F
AJR Am J Roentgenol; 2009 Jun; 192(6):1608-17. PubMed ID: 19457825
[TBL] [Abstract][Full Text] [Related]
13. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.
Su MY; Baik HM; Yu HJ; Chen JH; Mehta RS; Nalcioglu O
Technol Cancer Res Treat; 2006 Aug; 5(4):401-10. PubMed ID: 16866570
[TBL] [Abstract][Full Text] [Related]
14. Combined DCE-MRI and single-voxel 2D MRS for differentiation between benign and malignant breast lesions.
Lipnick S; Liu X; Sayre J; Bassett LW; Debruhl N; Thomas MA
NMR Biomed; 2010 Oct; 23(8):922-30. PubMed ID: 20878970
[TBL] [Abstract][Full Text] [Related]
15. Proton MR spectroscopy of the breast.
Tozaki M
Breast Cancer; 2008; 15(3):218-23. PubMed ID: 18443899
[TBL] [Abstract][Full Text] [Related]
16. MRI and (1)H MRS of the breast: presence of a choline peak as malignancy marker is related to K21 value of the tumor in patients with invasive ductal carcinoma.
Geraghty PR; van den Bosch MA; Spielman DM; Hunjan S; Birdwell RL; Fong KJ; Stables LA; Zakhour M; Herfkens RJ; Ikeda DM
Breast J; 2008; 14(6):574-80. PubMed ID: 19000051
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases.
Yeung DK; Yang WT; Tse GM
Radiology; 2002 Oct; 225(1):190-7. PubMed ID: 12355004
[TBL] [Abstract][Full Text] [Related]
18. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
Bartella L; Morris EA; Dershaw DD; Liberman L; Thakur SB; Moskowitz C; Guido J; Huang W
Radiology; 2006 Jun; 239(3):686-92. PubMed ID: 16603660
[TBL] [Abstract][Full Text] [Related]
19. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance spectroscopy of the breast: current status.
Bolan PJ
Magn Reson Imaging Clin N Am; 2013 Aug; 21(3):625-39. PubMed ID: 23928249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
